French independent pharma company Servier today announced the appointments of Christian Schubert and Rekha Paleyanda as directors of Servier BioInnovation along with the opening of the Servier BioInnovation office in Cambridge, Massachusetts. 7 June 2018
In what is becoming a growing trend, another big pharma senior executive has left to take on a position with a growing biotechnology company, this time to the advantage of Cambridge, Massachusetts-based Axcella Health and loss for Swiss giant Novartis. 31 May 2018
Privately-held dermatology specialist LEO Pharma today announced that Dr Christian Antoni has been appointed as senior vice president for global development at the Danish firm as of June 1, 2018. 29 May 2018
ArQule announced on Friday that it was strengthening its management team with the addition of two new senior vice presidents, former Citibank banking director Marc Schegerin and Shirish Hirani, a longstanding VP of drug development at Ariad Pharmaceuticals. 25 May 2018
Norbert Bischofberger has been named chief executive of Kronos Bio, one of the portfolio companies of venture capital firm and merchant bank Two River. 24 May 2018
Sensei Biotherapeutics, a privately-held company known as Panacea Pharmaceuticals until earlier this year, has announced the appointment of John Celebi as chief executive as the company seeks to push forward with its lead cancer vaccine. 16 May 2018
Horizon Discovery’s announcement on the identity of its new chief executive on Monday has been followed on Tuesday by a major drop in the share price of the gene editing company. 9 May 2018
French independent pharma company Pierre Fabre has named Eric Ducournau as its new chief executive, taking over from Bertrand Parmentier who has announced his retirement. 7 May 2018
US pharma major Eli Lilly today announced that Leena Gandhi, a prestigious thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology on June 25, 2018 to lead immuno-oncology medical development. 2 May 2018
Grünenthal has announced that Philip Just Larsen is to join the company chief scientific officer (CSO) and member of the corporate executive board. 30 April 2018
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024